Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 107Head & Neck 68Thoracic 49Genitourinary 24Breast 24Gynecologic 15Other solid neoplasm 13Dermatologic 11Lymphoid 5Tumor-Agnostic 4Sarcoma 4Other neoplasm 2CNS 2Endocrine 1

Conditions

Neoplasms 4

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × toripalimab × Tumor-Agnostic × Clear all
NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

West China Hospital

Phase 1 Active not recruiting
6 enrolled
Tumor-Agnostic

Neoplasms

NCT07004244 2025-06-24

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Sichuan University

Phase 1 Recruiting
20 enrolled
Tumor-Agnostic

Neoplasms

NCT06612632 2024-09-25

Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT05253105 2022-05-31

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡